| Q64821040 | Q64821040 |
| Q92155680 | A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy |
| Q92856615 | A New Projection From the Deep Cerebellar Nuclei to the Hippocampus via the Ventrolateral and Laterodorsal Thalamus in Mice |
| Q36854725 | A Therapeutic Role for Survivin in Mitigating the Harmful Effects of Ionizing Radiation |
| Q42252512 | A compact dual promoter adeno-associated viral vector for efficient delivery of two genes to dorsal root ganglion neurons. |
| Q45867380 | A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis |
| Q40916579 | A helper virus-free packaging system for recombinant adeno-associated virus vectors |
| Q40608616 | A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells |
| Q37568920 | A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications |
| Q45879506 | A realistic chance for gene therapy in the near future |
| Q28830946 | A synopsis on the role of tyrosine hydroxylase in Parkinson's disease |
| Q40838016 | A tyrosine hydroxylase-neurofilament chimeric promoter enhances long-term expression in rat forebrain neurons from helper virus-free HSV-1 vectors |
| Q39139260 | AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. |
| Q61976265 | AAV for disorders of the CNS |
| Q33822179 | AAV provides an alternative for gene therapy of the peripheral sensory nervous system |
| Q46455025 | AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease |
| Q45872572 | AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers |
| Q35114530 | AAV-mediated overexpression of neuroserpin in the hippocampus decreases PSD-95 expression but does not affect hippocampal-dependent learning and memory. |
| Q45885520 | AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. |
| Q38066256 | AAV2-neurturin (CERE-120) for Parkinson's disease |
| Q37690491 | AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. |
| Q36269315 | Aberrant Purkinje cell activity is the cause of dystonia in a shRNA-based mouse model of Rapid Onset Dystonia-Parkinsonism |
| Q92069614 | Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation |
| Q35095825 | Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala |
| Q45861223 | Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse |
| Q30885494 | Adeno-associated viral vectors and their redirection to cell-type specific receptors |
| Q33305143 | Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice |
| Q35216667 | Adeno-associated viral vectors for Parkinson's disease |
| Q33701559 | Adeno-associated viral vectors for gene transfer and gene therapy |
| Q35566831 | Adeno-associated viral vectors for retinal gene transfer. |
| Q35216648 | Adeno-associated viral vectors. |
| Q36802175 | Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis |
| Q45762593 | Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity |
| Q30497101 | Adeno-associated virus (AAV)-mediated suppression of Ca2+/calmodulin kinase IV activity in the nucleus accumbens modulates emotional behaviour in mice |
| Q34429058 | Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice |
| Q33933129 | Adeno-associated virus as a gene delivery system |
| Q39583470 | Adeno-associated virus as a vector for liver-directed gene therapy. |
| Q27012320 | Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective |
| Q34013197 | Adeno-associated virus effectively mediates conditional gene modification in the brain |
| Q40994121 | Adeno-associated virus expression systems for gene transfer |
| Q24634560 | Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 |
| Q30425244 | Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice |
| Q34070164 | Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo |
| Q24529167 | Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression |
| Q34472029 | Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo |
| Q33786039 | Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q35573761 | Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model |
| Q45728411 | Adeno-associated virus vector expressing nerve growth factor enhances cholinergic axonal sprouting after cortical injury in rats. |
| Q30306214 | Adeno-associated virus vector mediated gene transfer to pancreatic beta cells |
| Q33919915 | Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo |
| Q45730194 | Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product |
| Q45740016 | Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system |
| Q45711198 | Adeno-associated virus vector-mediated transduction in the cat brain |
| Q33695816 | Adeno-associated virus vectors and hematology |
| Q33958498 | Adeno-associated virus vectors: activity and applications in the CNS. |
| Q40683650 | Adeno-associated virus-mediated delivery of glial cell line-derived neurotrophic factor protects motor neuron-like cells from apoptosis |
| Q35015540 | Adeno-associated virus-mediated gene transfer for hemophilia B. |
| Q33807737 | Adeno-associated virus-mediated transfer of endothelial nitric oxide synthase gene reduces the vasoconstrictive response. |
| Q52197420 | Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus. |
| Q45861869 | Adenoviral vectors for in vivo gene delivery to oligodendrocytes: transgene expression and cytopathic consequences |
| Q40937700 | Adenovirus and adeno-associated virus as vectors for gene therapy |
| Q34656049 | Advances in gene therapy for movement disorders. |
| Q39587262 | Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model |
| Q37188128 | Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats |
| Q45855288 | Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord |
| Q33943954 | An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease |
| Q33790771 | An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells |
| Q37863587 | An update on gene therapy in Parkinson's disease |
| Q35877884 | Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products |
| Q44814719 | Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. |
| Q37585001 | Antisense gene silencing: therapy for neurodegenerative disorders? |
| Q45885532 | Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta |
| Q34987177 | Application of adeno-associated viral vectors in behavioral research |
| Q45856230 | Application of gene therapy to treat age-related loss of dopamine D2 receptor |
| Q40957115 | Applications of gene therapy to the CNS. |
| Q28703567 | Applying gene silencing technology to contraception |
| Q45869225 | Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease |
| Q33939090 | Astrocyte line SVG-TH grafted in a rat model of Parkinson's disease |
| Q44511379 | Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion |
| Q36381023 | Avian adeno-associated virus vector efficiently transduces neurons in the embryonic and post-embryonic chicken brain |
| Q40979834 | Axonal regeneration |
| Q37316887 | Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy |
| Q45883914 | Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats |
| Q40745277 | Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction |
| Q40466380 | Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability. |
| Q40933776 | Cellular contaminants of adeno-associated virus vector stocks can enhance transduction. |
| Q41561770 | Cellular immunotherapy and autologous transplantation for hematologic malignancy |
| Q45747525 | Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways |
| Q34003138 | Cellular transplants as sources for therapeutic agents |
| Q41623081 | Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. |
| Q37580174 | Chapter 11: Tissue engineering of peripheral nerves |
| Q45756120 | Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. |
| Q24523651 | Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue |
| Q47230840 | Cloning of a novel Apaf-1-interacting protein: a potent suppressor of apoptosis and ischemic neuronal cell death. |
| Q35892008 | Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. |
| Q64787878 | Co-grafts of muscle cells and mesencephalic tissue into hemiparkinsonian rats: behavioral and histochemical effects |
| Q37980864 | Cocaine hydrolase gene therapy for cocaine abuse |
| Q33782224 | Cochlear gene therapy: current perspectives |
| Q33577391 | Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brains |
| Q33822237 | Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons |
| Q34115783 | Comparison of the efficacy of five adeno-associated virus vectors for transducing dorsal raphé nucleus cells in the mouse |
| Q33823450 | Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. |
| Q36969304 | Correction of a Rat Model of Parkinson's Disease by Coexpression of Tyrosine Hydroxylase and Aromatic Amino Acid Decarboxylase from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector |
| Q34074791 | Current status of viral gene therapy for brain tumours |
| Q39876259 | DNA double-strand break repair functions defend against parvovirus infection. |
| Q33363531 | DNA shuffling of adeno-associated virus yields functionally diverse viral progeny |
| Q37724740 | Deciphering a neuronal circuit that mediates appetite |
| Q40913368 | Defective viral vectors as agents for gene transfer in the nervous system |
| Q40737427 | Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease |
| Q36200143 | Delivery of antiangiogenic agents for cancer gene therapy |
| Q45746815 | Delivery of herpes simplex virus amplicon-based vectors to the dentate gyrus does not alter hippocampal synaptic transmission in vivo |
| Q33296224 | Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer |
| Q40905804 | Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. |
| Q45222289 | Direct delivery of leptin to the hypothalamus using recombinant adeno-associated virus vectors results in increased therapeutic efficacy |
| Q45756222 | Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy |
| Q48526007 | Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. |
| Q64381079 | Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats |
| Q45877347 | Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts |
| Q28080611 | Drug and gene delivery across the blood-brain barrier with focused ultrasound |
| Q33825510 | Dynamin is required for recombinant adeno-associated virus type 2 infection |
| Q37613085 | Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates |
| Q45721911 | Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors |
| Q24797018 | Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors |
| Q36983576 | Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors |
| Q45151455 | Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. |
| Q45748024 | Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors |
| Q33713355 | Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates. |
| Q35872651 | Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector |
| Q36242842 | Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus |
| Q40949297 | Efficient production of adeno-associated virus vectors using split-type helper plasmids |
| Q24538483 | Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors |
| Q39528330 | Elastin-like polypeptide matrices for enhancing adeno-associated virus-mediated gene delivery to human neural stem cells |
| Q92635178 | Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy |
| Q33604753 | Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation |
| Q34862612 | Engineered lentiviral vector targeting astrocytes in vivo |
| Q62971299 | Engineering Herpes Simplex |
| Q47235611 | Enhanced Targeted Gene Transduction: AAV2 Vectors Conjugated to Multiple Aptamers via Reducible Disulfide Linkages. |
| Q45882831 | Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. |
| Q45408947 | Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. |
| Q34997245 | Enhancement of Recombinant Adeno-Associated Virus Type 2-Mediated Transgene Expression in a Lung Epithelial Cell Line by Inhibition of the Epidermal Growth Factor Receptor |
| Q39586854 | Evaluation of the specificity and sensitivity of ferritin as an MRI reporter gene in the mouse brain using lentiviral and adeno-associated viral vectors. |
| Q33844362 | Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo |
| Q51735646 | FGF1 improves functional recovery through inducing PRDX1 to regulate autophagy and anti-ROS after spinal cord injury. |
| Q42638545 | Fat grafting as a vehicle for the delivery of recombinant adenoassociated viral vectors to achieve gene modification of muscle flaps |
| Q45887146 | Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy |
| Q39548622 | Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. |
| Q37574414 | From microsurgery to nanosurgery: how viral vectors may help repair the peripheral nerve. |
| Q34152190 | Future directions in alcoholism research. Genomics and gene transfer. |
| Q37696495 | Future of cell and gene therapies for Parkinson's disease |
| Q40077177 | Gene Manipulation Strategies to Identify Molecular Regulators of Axon Regeneration in the Central Nervous System |
| Q55418920 | Gene Therapy for Parkinson's Disease, An Update. |
| Q35570276 | Gene Transfer Strategies for Correction of Lysosomal Storage Disorders |
| Q34179305 | Gene delivery and gene therapy with herpes simplex virus-based vectors |
| Q39098445 | Gene delivery targeted to oligodendrocytes using a lentiviral vector |
| Q45758902 | Gene delivery to rat enteric neurons using herpes simplex virus-based vectors |
| Q35943644 | Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein |
| Q33917592 | Gene delivery with viral vectors for cerebrovascular diseases |
| Q33953261 | Gene regulation in the magnocellular hypothalamo-neurohypophysial system |
| Q34446012 | Gene therapy against neurological insults: sparing neurons versus sparing function |
| Q64382253 | Gene therapy for Parkinson's disease |
| Q36150495 | Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors |
| Q34119491 | Gene therapy for Parkinson's disease: review and update |
| Q40825648 | Gene therapy for cerebrovascular disease |
| Q64379985 | Gene therapy for hemophilia |
| Q41332176 | Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 1. The bench |
| Q40905286 | Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 2. The bedside |
| Q85789509 | Gene therapy for psychiatric disorders |
| Q34997896 | Gene therapy for the central nervous system in the lysosomal storage disorders |
| Q56908635 | Gene therapy for the hemophilias |
| Q38166648 | Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications |
| Q34987206 | Gene therapy for treatment of cerebral ischemia using defective recombinant adeno-associated virus vectors |
| Q24680275 | Gene therapy in clinical medicine |
| Q35630146 | Gene therapy in orthopaedic surgery: the current status |
| Q99728073 | Gene therapy in the CNS-one size does not fit all |
| Q33837123 | Gene therapy in the CNS. |
| Q39550492 | Gene therapy vectors based on adeno-associated virus type 1. |
| Q34476794 | Gene therapy with herpes simplex virus vectors: progress and prospects for clinical neuroscience |
| Q40902734 | Gene therapy. Is the future here yet? |
| Q26772109 | Gene therapy: progress and predictions |
| Q33607774 | Gene transfer approaches to the lysosomal storage disorders |
| Q30440245 | Gene transfer in human vestibular epithelia and the prospects for inner ear gene therapy |
| Q33899454 | Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. |
| Q44109671 | Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression |
| Q34055904 | Gene transfer to the CNS using recombinant adeno-associated virus |
| Q45867822 | Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe |
| Q35286653 | Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models |
| Q44235491 | Generation of aberrant sprouting in the adult rat brain by GAP-43 somatic gene transfer |
| Q40952227 | Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain |
| Q45709087 | Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies |
| Q40905745 | Genetic therapy. Past, present, and future |
| Q34843808 | Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial |
| Q44874428 | Growth factor enhanced retroviral gene transfer to the adult central nervous system |
| Q36004744 | Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90 |
| Q35870965 | Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. |
| Q35216671 | Herpes simplex virus vectors for Parkinson's disease |
| Q64789924 | Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system |
| Q40933793 | High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. |
| Q35891440 | Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. |
| Q34447817 | Hot topics in adeno-associated virus as a gene transfer vector |
| Q31023442 | Human gene therapy and imaging in neurological diseases |
| Q35900639 | Hypothalamic Fkbp51 is induced by fasting, and elevated hypothalamic expression promotes obese phenotypes |
| Q45446011 | IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes |
| Q40922367 | Immune responses to adenovirus vectors in the nervous system |
| Q35000819 | Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain |
| Q33796712 | Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts |
| Q35085243 | Improved survival of ischemic cutaneous and musculocutaneous flaps after vascular endothelial growth factor gene transfer using adeno-associated virus vectors |
| Q40121209 | Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors |
| Q36825641 | In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector |
| Q48529105 | In vivo gene transfer into the adult mammalian central nervous system by continuous injection of plasmid DNA-cationic liposome complex |
| Q38824171 | In vivo tissue-tropism of adeno-associated viral vectors |
| Q45869654 | Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain |
| Q40369829 | Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model |
| Q35193397 | Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy |
| Q104516383 | Innovative Applications of MR-Guided Focused Ultrasound for Neurological Disorders |
| Q37082190 | Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users |
| Q42872720 | Intracranial Injection of Adeno-associated Viral Vectors |
| Q48702567 | Intrastriatal grafts of embryonic mesencephalic rat neurons genetically modified using an adenovirus encoding human Cu/Zn superoxide dismutase |
| Q35119851 | Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation |
| Q43890874 | Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector |
| Q44974102 | Introduction of the glutamate receptor subunit 1 into motor neurons in vitro and in vivo using a recombinant herpes simplex virus |
| Q40196434 | Isolation of an enhancer from the rat tyrosine hydroxylase promoter that supports long-term, neuronal-specific expression from a neurofilament promoter, in a helper virus-free HSV-1 vector system |
| Q33815070 | Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver |
| Q33802149 | Kinetics of recombinant adeno-associated virus-mediated gene transfer |
| Q37265519 | Large animal models of neurological disorders for gene therapy |
| Q24527302 | Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model |
| Q24289526 | Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations |
| Q37778403 | Leptin gene therapy in the fight against diabetes |
| Q38344127 | Leptin-receptor gene transfer into the arcuate nucleus of female Fatty zucker rats using recombinant adeno-associated viral vectors stimulates the hypothalamo-pituitary-gonadal axis |
| Q40707011 | Light-activated gene transduction enhances adeno-associated virus vector-mediated gene expression in human articular chondrocytes |
| Q48165069 | Lipid mediated gene delivery in the adult rat brain: quantitative analysis of expression |
| Q45880758 | Lipofectin-facilitated transfer of cholecystokinin gene corrects behavioral abnormalities of rats with audiogenic seizures |
| Q38078421 | Liposomes for brain delivery |
| Q44903416 | Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain |
| Q35947942 | Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity |
| Q37378737 | Local knockdown of ERK2 in the adult mouse brain via adeno-associated virus-mediated RNA interference. |
| Q40321814 | Long-term adeno-associated viral vector-mediated expression of truncated TrkB in the adult rat facial nucleus results in motor neuron degeneration. |
| Q33735882 | Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin |
| Q35734505 | Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. |
| Q45765859 | Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector |
| Q40874496 | Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. |
| Q43535625 | Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease |
| Q40561045 | MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma |
| Q74587447 | Manipulation of gene expression in the mammalian nervous system: application in the study of neurite outgrowth and neuroregeneration-related proteins |
| Q41838643 | Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice |
| Q35550669 | Metabolic Engineering: Advances in Modeling and Intervention in Health and Disease |
| Q35902332 | Methods for gene transfer to the central nervous system |
| Q33745707 | Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats |
| Q40312569 | Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells |
| Q34657654 | Models of repair mechanisms for future treatment modalities of Parkinson's disease. |
| Q35563389 | Molecular biology and gene therapy in the treatment of chronic pain. |
| Q33492733 | Molecular evolution of adeno-associated virus for enhanced glial gene delivery |
| Q35674368 | Molecular medicine for the brain: silencing of disease genes with RNA interference |
| Q39182534 | Molecular therapy for renal diseases |
| Q24515072 | Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism |
| Q48479929 | NGF gene expression in dividing and non-dividing cells from AAV-derived constructs |
| Q36696450 | Nanotechnology in corneal neovascularization therapy--a review |
| Q37181003 | Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. |
| Q37931558 | Nerve surgery and gene therapy: a neurobiological and clinical perspective. |
| Q40915172 | Neuronal-specific and nerve growth factor-inducible expression directed by the preprotachykinin-A promoter delivered by an adeno-associated virus vector |
| Q41634721 | New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors |
| Q27312535 | Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound |
| Q33985663 | Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders |
| Q43708764 | Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction |
| Q42155660 | Novel subventricular zone early progenitor cell-specific adenovirus for in vivo therapy of central nervous system disorders reinforces brain stem cell heterogeneity. |
| Q41671598 | Novel therapeutic directions for Parkinson's disease |
| Q45743733 | Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus |
| Q38302918 | Optimised helper virus-free production of high-quality adeno-associated virus vectors |
| Q44586325 | Optimization of packaging of adeno-associated virus gene therapy vectors using plasmid transfections |
| Q40793707 | Optimization of recombinant adeno-associated virus production using an herpes simplex virus amplicon system |
| Q42442484 | Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy |
| Q45742577 | Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization |
| Q45340200 | Overexpression of CART in the PVN increases food intake and weight gain in rats |
| Q43139168 | Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity |
| Q24292718 | PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein |
| Q34355457 | Parkinson disease: etiology, pathogenesis and future of gene therapy |
| Q34609626 | Parvovirus-mediated gene transfer for the haemophilias |
| Q45753463 | Peroral gene therapy of lactose intolerance using an adeno-associated virus vector |
| Q43716886 | Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors |
| Q24683259 | Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors |
| Q44686121 | Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats |
| Q59137624 | Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion |
| Q38073822 | Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. |
| Q52589683 | Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. |
| Q40442947 | Possible orthopaedic applications of gene therapy |
| Q35884195 | Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector |
| Q38960704 | Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes |
| Q45723727 | Prevention of Chronic Deterioration of Heart Allograft by Recombinant Adeno-Associated Virus-Mediated Heme Oxygenase-1 Gene Transfer |
| Q41025144 | Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro |
| Q34150872 | Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression |
| Q34090316 | Primate models of schizophrenia: future possibilities |
| Q24523073 | Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus |
| Q40937480 | Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus |
| Q34987192 | Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain |
| Q33843651 | Prospects for genetic therapy of cardiovascular disease |
| Q37082158 | Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse |
| Q45871733 | Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors |
| Q45735544 | Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. |
| Q38081701 | RNA viruses and the host microRNA machinery |
| Q34694806 | Random Insertion of mCherry Into VP3 Domain of Adeno-associated Virus Yields Fluorescent Capsids With no Loss of Infectivity |
| Q30495536 | Rapid, long-term labeling of cells in the developing and adult rodent visual cortex using double-stranded adeno-associated viral vectors. |
| Q45864411 | Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain |
| Q45886584 | Recombinant AAV vector encoding human VEGF165 enhances wound healing. |
| Q45736758 | Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons |
| Q45007196 | Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system |
| Q40933734 | Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy |
| Q40616143 | Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development |
| Q91707074 | Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? |
| Q40434024 | Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes In vitro and In vivo. |
| Q28386583 | Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia |
| Q36368045 | Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. |
| Q45764433 | Recombinant adeno-associated virus for muscle directed gene therapy |
| Q35111738 | Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. |
| Q34987182 | Recombinant adeno-associated virus vector design and gene expression in the mammalian brain |
| Q34472181 | Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS |
| Q35842668 | Recombinant adeno-associated virus vectors for gene therapy |
| Q35869915 | Recombinant adeno-associated virus-mediated high-efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors. |
| Q33654870 | Recombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood |
| Q33970439 | Recombinant adenoassociated virus in cancer gene therapy |
| Q38338178 | Reduced MK801 binding in neocortical neurons after AAV-mediated transfections with NMDA-R1 antisense cDNA. |
| Q34361466 | Regulatable and cell-type specific transgene expression in glial cells: prospects for gene therapy for neurological disorders |
| Q36948756 | Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? |
| Q92987777 | Regulated hAAT Expression from a Novel rAAV Vector and Its Application in the Prevention of Type 1 Diabetes |
| Q33823405 | Repeated delivery of adeno-associated virus vectors to the rabbit airway |
| Q40228737 | Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth |
| Q47832394 | Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector |
| Q33545312 | Restorative gene therapy approaches to Parkinson's disease |
| Q36144795 | Retargeting transposon insertions by the adeno-associated virus Rep protein. |
| Q30497984 | Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens |
| Q31045537 | Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer |
| Q39880225 | Role for highly regulated rep gene expression in adeno-associated virus vector production |
| Q34640765 | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial |
| Q40825421 | Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). |
| Q37596958 | Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors |
| Q42401422 | Select overexpression of homer1a in dorsal hippocampus impairs spatial working memory |
| Q45727079 | Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors |
| Q35431994 | Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges |
| Q90178596 | Sequential two-step chromatographic purification of infectious poliovirus using ceramic fluoroapatite and ceramic hydroxyapatite columns |
| Q36508670 | Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex |
| Q45867578 | Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice |
| Q37246710 | Site-specific integration by adeno-associated virus |
| Q39580779 | Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. |
| Q38121120 | Small RNA drugs for prion disease: a new frontier |
| Q41450039 | Somatic gene transfer approaches to manipulate neural networks |
| Q36631977 | Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity |
| Q44208360 | Specific and efficient transduction of Cochlear inner hair cells with recombinant adeno-associated virus type 3 vector |
| Q38255644 | Spinal cord injury and the neuron-intrinsic regeneration-associated gene program |
| Q36159178 | Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus |
| Q36804579 | Stereotaxic injection of a viral vector for conditional gene manipulation in the mouse spinal cord |
| Q42007195 | Stereotaxic microinjection of viral vectors expressing Cre recombinase to study the role of target genes in cocaine conditioned place preference |
| Q45867412 | Strategies for CNS-directed gene delivery: in vivo gene transfer to the brain using SV40-derived vectors |
| Q40967721 | Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy |
| Q40643169 | Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. |
| Q33786029 | Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure |
| Q43848028 | Summary report of a symposium: genes and gene delivery for diseases of alcoholism |
| Q36341646 | Super-resolution imaging of nuclear import of adeno-associated virus in live cells |
| Q37360120 | Supernova: A Versatile Vector System for Single-Cell Labeling and Gene Function Studies in vivo. |
| Q48348307 | Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in the facial nucleus of the rat. |
| Q41941382 | Surface immobilization of hexa-histidine-tagged adeno-associated viral vectors for localized gene delivery |
| Q35460836 | Surgical method for virally mediated gene delivery to the mouse inner ear through the round window membrane |
| Q45862567 | Sustained gene expression in transplanted skin fibroblasts in rats |
| Q40969562 | Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody |
| Q28710390 | Targeted gene silencing to induce permanent sterility |
| Q45888386 | Targeted integration of a recombinant globin gene adeno-associated viral vector into human chromosome 19. |
| Q37238775 | Targeting Homer genes using adeno-associated viral vector: lessons learned from behavioural and neurochemical studies. |
| Q34942440 | Techniques for gene transfer into neurons. |
| Q92698789 | The Configuration of the Perivascular System Transporting Macromolecules in the CNS |
| Q64331910 | The Effect of Recombinant Tyrosine Hydroxylase Expression on the Neurogenic Differentiation Potency of Mesenchymal Stem Cells |
| Q35886582 | The Rep78 gene product of adeno-associated virus (AAV) self-associates to form a hexameric complex in the presence of AAV ori sequences |
| Q38004089 | The advent of AAV9 expands applications for brain and spinal cord gene delivery |
| Q37298417 | The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector |
| Q36337994 | The assessment of adeno-associated vectors as potential intrinsic treatments for brainstem axon regeneration |
| Q37814051 | The complex and evolving story of T cell activation to AAV vector-encoded transgene products |
| Q38693865 | The histidine-rich peptide LAH4-L1 strongly promotes PAMAM-mediated transfection at low nitrogen to phosphorus ratios in the presence of serum |
| Q35000529 | The magnocellular neuronal phenotype: cell-specific gene expression in the hypothalamo-neurohypophysial system |
| Q43860392 | The neurobiology of social recognition, approach, and avoidance |
| Q45756377 | The use of heterologous promoters for adeno-associated virus (AAV) protein expression in AAV vector production |
| Q39617892 | The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex |
| Q26746174 | Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease |
| Q35112002 | Therapeutic Gene Transfer to the Nervous System Using Viral Vectors |
| Q44084438 | Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease |
| Q35542643 | Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity |
| Q43567043 | Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. |
| Q34105795 | Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model |
| Q45890373 | Towards gene therapy for the central nervous system |
| Q35889903 | Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. |
| Q42200227 | Transduction efficiency of neurons and glial cells by AAV-1, -5, -9, -rh10 and -hu11 serotypes in rat spinal cord following contusion injury |
| Q33782809 | Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers |
| Q45884333 | Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors |
| Q42450986 | Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response |
| Q39594915 | Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. |
| Q24684374 | Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis |
| Q35570267 | Transgenesis and the Study of Expression, Cellular Targeting and Function of Oxytocin, Vasopressin and Their Receptors |
| Q41139955 | Transient gene transfer to neurons and glia: analysis of adenoviral vector performance in the CNS and PNS. |
| Q36739755 | Translational considerations for CNS gene therapy |
| Q34381586 | Transneuronal tracing of diverse CNS circuits by Cre-mediated induction of wheat germ agglutinin in transgenic mice |
| Q44515156 | Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses |
| Q34399110 | Treatment of GM2 gangliosidosis: past experiences, implications, and future prospects |
| Q28273702 | Tyrosine hydroxylase and Parkinson's disease |
| Q48315993 | Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain |
| Q36370376 | Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice |
| Q41349101 | Vectors for cancer gene therapy |
| Q35122178 | Vectors for the treatment of autoimmune disease. |
| Q34285870 | Versatile somatic gene transfer for modeling neurodegenerative diseases |
| Q64381642 | Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice |
| Q30495981 | Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression |
| Q101038935 | Viral tools for neuroscience |
| Q36787828 | Viral vector-based gene transfer for treatment of chronic pain |
| Q56947120 | Viral vector-mediated gene therapy for Parkinson's disease |
| Q35618384 | Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. |
| Q37946113 | Viral vectors for gene delivery to the central nervous system |
| Q45889833 | Viral vectors for gene therapy |
| Q32113689 | Viral vectors for gene therapy in Parkinson's disease |
| Q28138453 | Viral vectors for gene transfer: a review of their use in the treatment of human diseases |
| Q41235446 | Viral vectors for modulating gene expression in neurons |
| Q33894621 | Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS |
| Q33816851 | Viral vectors in the treatment of Parkinson's disease |
| Q34446026 | Viral-based gene transfer to the mammalian CNS for functional genomic studies |
| Q45883103 | Viral-mediated gene transfer in the cochlea |
| Q36951265 | Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector |
| Q71854154 | [Gene therapy of nervous system diseases in children] |
| Q28144597 | rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy |
| Q39731043 | rAAV-mediated delivery of brain-derived neurotrophic factor promotes neurite outgrowth and protects neurodegeneration in focal ischemic model |